In the preceding three months, 4 analysts have released ratings for Regenxbio (NASDAQ:RGNX), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $36.5, a high estimate of $50.00, and a low estimate of $18.00. Experiencing a 17.05% decline, the current average is now lower than the previous average price target of $44.00.
Investigating Analyst Ratings: An Elaborate Study
In examining recent analyst actions, we...
Login or create a forever free account to read this news
Sign up/Log in
